These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 25689069)

  • 21. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
    Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
    Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
    Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
    Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study on the distribution of CD8+ memory T cell subsets and IFN-γ level during the spontaneous clearance of hepatitis B virus in patients with chronic hepatitis B virus infection.
    Ma XJ; Chen XF; Chen WL; Chen R; Huang J; Luo XD; Liao JY; Chen XP
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4675-4679. PubMed ID: 29131246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir.
    Fong TL; Tien A; Jo KJ; Chu D; Cheung E; Mena EA; Phan QQ; Yu AS; Mohammed W; Velasco A; LeDuc VH; Nguyen N; Han SB; Chang M; Bae HS; Cho YW; Tong MJ; Cooper SL
    Dig Dis Sci; 2015 Nov; 60(11):3465-72. PubMed ID: 26138653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy.
    Chaung KT; Ha NB; Trinh HN; Garcia RT; Nguyen HA; Nguyen KK; Garcia G; Ahmed A; Keeffe EB; Nguyen MH
    J Clin Gastroenterol; 2012; 46(10):865-70. PubMed ID: 22941429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effect of maternal HBeAg on delayed HBeAg seroconversion in offspring with chronic hepatitis B infection.
    Tseng YR; Wu JF; Ni YH; Chen HL; Chen CC; Wen WH; Hsu HY; Chang MH
    Liver Int; 2011 Oct; 31(9):1373-80. PubMed ID: 21745315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of spontaneous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients during the immune clearance phase.
    Song G; Rao H; Feng B; Wei L
    J Med Virol; 2014 Nov; 86(11):1838-44. PubMed ID: 25088043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Precore wild-type DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion.
    Maruyama T; Kuwata S; Koike K; Iino S; Yasuda K; Yotsuyanagi H; Moriya K; Maekawa H; Yamada H; Shibata Y; Milich DR
    Hepatology; 1998 Jan; 27(1):245-53. PubMed ID: 9425944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of pre-core and basal core promoter before and after hepatitis B e antigen seroconversion.
    Kamijo N; Matsumoto A; Umemura T; Shibata S; Ichikawa Y; Kimura T; Komatsu M; Tanaka E
    World J Gastroenterol; 2015 Jan; 21(2):541-8. PubMed ID: 25593470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of HBeAg and HBsAg seroconversion in patients with chronic hepatitis B.
    Stránský J; Chlumská A; Zichová M; Helm R; Mankovecký L; König J
    Sb Lek; 1993; 94(4):317-25. PubMed ID: 7992018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters.
    Tseng TC; Liu CJ; Chen CL; Wang CC; Su TH; Kuo SF; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2012 Jan; 205(1):54-63. PubMed ID: 22095766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.
    Alexander G; Baba CS; Chetri K; Negi TS; Choudhuri G
    BMC Gastroenterol; 2005 Sep; 5():29. PubMed ID: 16164746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of enlarged perihepatic lymph nodes in chronic hepatitis B.
    Choi MS; Lee JH; Koh KC; Paik SW; Rhee PL; Kim JJ; Rhee JC; Choi KW; Kim SH
    J Clin Gastroenterol; 2001 Apr; 32(4):329-32. PubMed ID: 11276277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Epidemiological characteristics of HBeAg reversion in chronic hepatitis B patients with HBeAg seroconversion in Jiangsu province, 2012-2014].
    Zhu LG; Tian H; Jiang J; Song C; Zou Y; Xu JF; Liu HJ; Peng H; Hu ZB; Zhu FC; Shen HB; Zhai XJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jan; 38(1):43-48. PubMed ID: 28100375
    [No Abstract]   [Full Text] [Related]  

  • 38. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients.
    He D; Guo S; Zhu P; Tao S; Li M; Huang H; Wang J; Wang Y; Ding M
    Clin Microbiol Infect; 2014 Oct; 20(10):O687-93. PubMed ID: 25469947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
    Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.